Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.…
Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences (NASDAQ: SGMT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 16 employees.
The shares were at 9.080 USD on 20 November 2026, up 18.1% over 52 weeks. Its 52-week range is 4.500 USD to 11.45 USD: the price is 20.7% below the high and 101.8% above the low.
Its market capitalisation is 648.02M USD.
Sagimet Biosciences reports return on equity of -45.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 234.38M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 27.27 USD is 200.4% above the current price. The next earnings report is expected on 11 March 2027.